Wayne Memorial Offers Innovative Full Spectrum Endoscopy® Procedure for Increased Visualization of the Colon Facility is one of the first in the nation to use EndoChoice’s (NYSE:GI) Fuse® endoscope system

Jesup, GA – Although colonoscopy exams prevent many colon cancer deaths[1] and are the gold standard, for detecting colorectal cancers [2], the procedure is not completely effective in preventing cancer cases [3] For this reason, Wayne Memorial has invested in an innovative technology that allows doctors to see nearly twice the anatomy seen with a traditional, forward-viewing endoscope.

The Fuse endoscope system from EndoChoice®, Inc. uses three small cameras at the tip of a flexible GI endoscope. “Unlike standard, forward-viewing endoscopes that use a single camera, the Fuse system lets doctors see nearly twice as much surface area,” said Pam White, Director of the Operating Room.

“The Fuse endoscope is all about seeing more of the GI tract. It projects the expanded view on three screens to give physicians previously unseen views, such as behind colonic folds and difficult anatomy. We are pleased to offer this important new technology to our community.”

The Fuse system was cleared by the FDA in the U.S. “As an early adopter of the innovative Fuse system, Wayne Memorial is at the forefront of U.S. healthcare providers offering the best technology and procedures for detecting colorectal cancers,” said White. “Our team is proud to be using the new system in our ongoing effort to reduce cancer and provide the highest quality care to our patients.”

In a multi-center trial conducted in the U.S., Europe and Israel, researchers performed a series of colonoscopies comparing standard, forward-viewing endoscopes and the new Fuse® system.

The endoscope used in the first examination was selected randomly. After the first inspection, each patient immediately underwent a second colonoscopy performed by the same doctor, but with the competing endoscope. The 185 patient trial showed standard, forward-viewing endoscopes missed 41% of potentially pre-cancerous lesions, or adenomas, while the Fuse system missed just 7%. Additionally, Fuse found 69% more adenomas when compared to standard, forward-viewing endoscopes. The results of this clinical study were recently published in The Lancet Oncology.

“Standard, forward-viewing endoscopes provide up to 170 degrees of forward vision. The advantage of Fuse is that it allows endoscopists to examine twice the anatomy with a wide 330 degree view. This is especially advantageous because adenomas can be missed in difficult to find areas of the anatomy,” said White. “The findings are compelling and support the data from previous studies showing the limitations of standard, forward-viewing endoscopes. EndoChoice’s innovative Fuse technology can dramatically improve the effectiveness of this life-saving procedure. And improving the effectiveness of every procedure we perform here at Wayne Memorial is what we’re all about.”

Patient scheduling with the new Fuse system is now underway at Wayne Memorial. More than 15 million colonoscopies are performed across the United States each year and most insurance companies cover the costs for those patients over age 50.

About Wayne Memorial
Wayne Memorial Hospital, whose mission is to provide high quality health care services to all patients, built a state-of-the-art facility in 2007. It is the fourth largest employer in Wayne County with 400 employees, 84 beds and is a two-time winner of the Georgia Alliance of Community Hospitals Small Hospital of the Year Award.

About EndoChoice

Based near Atlanta, EndoChoice (NYSE: GI) is a medtech company focused on the manufacturing and commercialization of platform technologies including endoscopic imaging systems, devices and infection control products and pathology services for specialists diagnosing and treating a wide range of gastrointestinal conditions, including colon cancer. EndoChoice leverages its direct sales organization to serve more than 2,500 customers in the United States and works with distribution partners in 25 countries. The Company was founded in 2008 and has rapidly developed a broad and innovative product portfolio, which includes the Full Spectrum Endoscopy System (Fuse®).
To learn more, visit www.endochoice.com

EndoChoice, Fuse, and Full Spectrum Endoscopy are registered trademarks of EndoChoice Holdings, Inc.